Core Competency
The company has been listed on the 2013 Top 100 Chinese Pharmaceutical Industry Companies.
Release time:
2014-06-23 16:35
Recently, the Pharmaceutical Economic Report of the Southern Institute of Pharmaceutical Economics exclusively released the 2013 Top 100 Chinese Pharmaceutical Industry List, and our company was listed among them.
This ranking is widely regarded as the most credible in the industry, comprehensively and scientifically reflecting the overall strength of enterprises. It is understood that the 2013 ranking was based on data collected from January 1 to December 31, 2013, with the statistical criteria being the annual sales revenue generated by the pharmaceutical industry. Participating companies were those registered within China (excluding subsidiaries of multinational pharmaceutical companies operating in China) and whose primary business activity was pharmaceutical manufacturing.
As a modern inheritor of Tibetan medicine and its culture, our company has always been committed to advancing contemporary Tibetan medicine. Through continuous exploration of time-tested remedies and innovative manufacturing technologies, we focus on developing new products. By employing standardized approaches, we highlight the unique therapeutic efficacy of Tibetan medicine and leverage cost-effectiveness to benefit the broader public. In this way, Tibetan medicine and its culture can secure their rightful place in modern society, ushering in an era of mass consumption—transforming the once-exclusive, mysterious Tibetan medicines enjoyed by high-ranking officials and nobles into accessible, everyday choices for ordinary people, and accelerating the industrial modernization of traditional Tibetan medicine. In 2013, the company achieved sales revenue of 969 million yuan, with core pharmaceutical business revenue reaching 700 million yuan, demonstrating sustained growth in our core operations. Sales revenue from our flagship product, the Xiaotong Paste, increased by 105 million yuan. The company recorded an operating profit of 220 million yuan and a net profit of 211 million yuan; net profit attributable to shareholders of the listed company reached 213 million yuan, representing a year-on-year increase of 12.20%. To date, the company has paid a total of 221 million yuan in taxes, an increase of 79.73 million yuan compared to the same period last year. Of this amount, 202 million yuan was paid in the Tibet region, marking the first time that tax payments in Tibet have exceeded 200 million yuan.
In recent years, with the shift toward a modern medical model and the growing demand for preventive healthcare, traditional medicine has attracted widespread public attention, and global demand for traditional medicine continues to rise. Domestically, as the “12th Five-Year Plan” for healthcare reform steadily progresses, a brand-new landscape is emerging in the primary healthcare market. Looking ahead, our company will focus on the Tibetan medicine business, with pain-relief plaster patches serving as our flagship Tibetan medicinal product. We are committed to becoming a leader in the field of topical pain relief, while also expanding our product portfolio to cover multiple therapeutic areas including orthopedics, gynecology, and neurology. Over the coming years, we will systematically grow and strengthen our presence in the pharmaceutical retail market, building structural competitive advantages in specialized therapeutic fields such as orthopedics, gynecology, and neurology, thereby ensuring that our pharmaceutical business continues to maintain an industry-leading growth rate.
Copyright Qizheng Tibetan Medicine Co., Ltd. All rights reserved. ICP Filing Number:
Internet drug information service qualification certificate number:（藏） Non-Commercial - 2018-0004 SEO